Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Open-label, Active-controlled, Dose-range Finding Study to Assess the Pharmacodynamic Parameters, Safety and Tolerability of MAA868 and Its Effect on Thrombogenesis Biomarkers Compared to Apixaban in Patients With Atrial Fibrillation

Trial Profile

A Multicenter, Randomized, Open-label, Active-controlled, Dose-range Finding Study to Assess the Pharmacodynamic Parameters, Safety and Tolerability of MAA868 and Its Effect on Thrombogenesis Biomarkers Compared to Apixaban in Patients With Atrial Fibrillation

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2018

At a glance

  • Drugs MAA 868 (Primary) ; Apixaban
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
  • Most Recent Events

    • 03 Oct 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 28 Sep 2018 Status changed from withdrawn prior to enrolment to not yet recruiting.
    • 10 Sep 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top